title: Treatment of a patient with adnexal lymphoma with Rituximab.
abstract: Orbital lymphoma is a very rare type of primary Non-Hodgkin lymphoma. The disorder is often small B-cell lymphoma, although large cell morphology may also be identified in rare cases. It may sometimes be confused with non-malignant, benign-course lymphoid hyperplasia. Although involvement is usually unilateral (80%), bilateral cases are also reported. Response to radiotherapy is achieved in the majority of cases, whereas the prognosis is poor in orbital involvement with large cell lymphoma and response to combined chemotherapy is inadequate. In this paper, we report a case with a diagnosis of unilateral adnexal involvement, who previously received CHOP treatment and developed a relapse 6 months later, then responded to treatment with Rituximab.
authors.affiliation: Department of 2nd Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey. obilgir2001@yahoo.com
authors.forename: Oktay
authors.initials: O
authors.lastname: Bilgir
authors.forename: Ferda
authors.initials: F
authors.lastname: Bilgir
authors.forename: Mehmet
authors.initials: M
authors.lastname: Calan
authors.forename: Arif
authors.initials: A
authors.lastname: Yuksel
authors.forename: Ferit
authors.initials: F
authors.lastname: Sari
authors.forename: Ozgür
authors.initials: O
authors.lastname: Oztekin
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000378:metabolism; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008223:Lymphoma; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009918:Orbital Neoplasms / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone